Exome Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Exome Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-987	Closed	-$305K	–	72
2024 Q4	$305K	Buy	+987	New	+$278K	0.23%	55
2024 Q3	–	Sell	-10,800	Closed	-$3.03M	–	74
2024 Q2	$3.03M	Buy	10,800 +2,900	+37%	+$690K	2.69%	10
2024 Q1	$2.11M	Sell	7,900 -5,302	-40%	-$1.25M	1.81%	19
2023 Q4	$3.05M	Buy	+13,202	New	+$2.31M	3.02%	10

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Exome Asset Management's MDGL Position: Q1 2025 in Review

Exome Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2025, closing a stake of 987 shares — an estimated $305K sold.

Exome Asset Management first reported a position in MDGL in Q4 2023 and held it in 4 quarters. The position peaked at $3.05M in Q4 2023. 321 funds tracked by Wall St. Rank hold MDGL as of Q1 2025.

Exome Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Exome Asset Management sold 987 Madrigal Pharmaceuticals shares in Q1 2025, an estimated $305K.
Exome Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 4 quarters.
Exome Asset Management's Madrigal Pharmaceuticals position peaked at $3.05M in Q4 2023.
321 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.